A novel combined micellar system of lapatinib and paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro

Journal of Pharmaceutical Sciences

Volumn 104, Issue 1, 2015, Pages 165-177

  Wei, Yan ^a   Xu, Shuai ^b   Wang, Feng ^c   Zou, Aifeng ^d   Zhang, Shuang ^a   Xiong, Yan ^a   Cao, Shilei ^a   Zhang, Qizhi ^a   Wang, Yajie ^b   Jiang, Xinguo ^a  

^a FUDAN UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY   (China)

^d Yangtze River Pharmaceutical Group   (China)

Author keywords

Cancer chemotherapy; Conjugation; Human epidermal growth factor receptor 2; Lapatinib; Micelle; Paclitaxel; Polymeric drug delivery systems; Poorly water soluble drugs; Sensitize; Solubility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MACROGOL; PACLITAXEL; POLYLACTIC ACID; SILICA GEL; DRUG CARRIER; DRUG COMBINATION; ERBB2 PROTEIN, HUMAN; LACTIC ACID; MACROGOL DERIVATIVE; MICELLE; POLYMER; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CANCER CELL; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DELAYED DRUG RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOSOME; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICELLE; PARTICLE SIZE; PROTON NUCLEAR MAGNETIC RESONANCE; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ZETA POTENTIAL; BREAST NEOPLASMS; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; DRUG FORMULATION; ENDOCYTOSIS; FEMALE; METABOLISM; PATHOLOGY; SOLUBILITY; SURFACE PROPERTY; TUMOR CELL LINE;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG CARRIERS; DRUG COMBINATIONS; DRUG COMPOUNDING; ENDOCYTOSIS; FEMALE; HUMANS; LACTIC ACID; MICELLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMERS; QUINAZOLINES; RECEPTOR, ERBB-2; SOLUBILITY; SURFACE PROPERTIES;

EID: 84919809204     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24234     Document Type: Article

References (31)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917.
2. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. 1986. Similarity of protein encoded by the human C-ERB-B-2 gene to epidermal growth-factor receptor. Nature 319(6050):230-234.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177-182.
4. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. 1992. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 12(2):419-425.
5. Singla AK, Garg A, Aggarwal D. 2002. Paclitaxel and its formulations. Int J Pharm 235(PII S0378-5173 (01) 00986-31-2):179-192.
6. Yu DH, Liu BL, Tan M, Li JZ, Wang SS, Hung MC. 1996. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 13(6):1359-1365.
7. Ueno NT, Yu DH, Hung MC. 1997. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. Oncogene 15(8):953-960.
8. Xia WL, Gerard CM, Liu LH, Baudson NM, Ory TL, Spector NL. 2005. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24(41):6213-6221.
9. Xia WL, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, Owens G, Alligood KJ, Spector NL. 2002. Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21(41):6255-6263.
10. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, Page M, Smith KJ, Guntrip SB, Carter MC, Shaw RJ, Jowett A, Stables J, Topley P, Wood ER, Brignola PS, Kadwell SH, Reep BR, Mullin RJ, Alligood KJ, Keith BR, Crosby RM, Murray DM, Knight WB, Gilmer TM, Lackey K. 2001. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer. Cancer Res 61(19):7196-7203.
11. Dai C, Tiwari AK, Wu C, Su X, Wang S, Liu D Jr, Ashby CR, Huang Y, Robey RW, Liang Y, Chen L, Shi C, Ambudkar SV, Chen Z, Fu L. 2008. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 68(19):7905-7914.
12. Castaneda CA, Gomez HL. 2009. Combined lapatinib and paclitaxel in HER2-positive breast cancer. Nat Rev Clin Oncol 6(6):308-309.
13. Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, Manikhas A, Pienkowski T, DeSilvio M, Ridderheim M, Abbey R. 2010. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology-Basel 79(1-2):129-135.
14. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF. 2008. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as firstline treatment for metastatic breast cancer. J Clin Oncol 26(34):5544-5552.
15. Gao H, Wang Y, Chen C, Chen J, Wei Y, Cao S, Jiang X. 2014. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 461(1-2):478-488.
16. Tarr BD, Yalkowsky SH. 1987. A new parenteral vehicle for the administration of some poorly water soluble anti-cancer drugs. J Parenter Sci Technol 41(1):31-33.
17. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Vanecho DA, Vonhoff DD, Leylandjones B. 1990. Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263-1268.
18. Jones MC, Leroux JC. 1999. Polymeric micelles-A new generation of colloidal drug carriers. Eur J Pharm Biopharm 48(2):101-111.
19. Zhang XC, Jackson JK, Burt HM. 1996. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int J Pharm 132(1-2):195-206.
20. Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J Control Release 72(1-3):191-202.
21. Han LM, Guo J, Zhang LJ, Wang QS, Fang XL. 2006. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 27(6):747-753.
22. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. 2009. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9(5):1909-1915.
23. Vergara D, Bellomo C, Zhang X, Vergaro V, Tinelli A, Lorusso V, Rinaldi R, Lvov YM, Leporatti S, Maffia M. 2012. Lapatinib/paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine 8(6):891-899.
24. Feng Li, Danquah M, Singh S, Wu H, Mahato R. 2011. Paclitaxeland lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Deliv Transl Res 1(6):420-428.
25. Mahmoudi M, Lynch I, Ejtehadi MR, Monopoli MP, Bombelli FB, Laurent S. 2011. Protein-nanoparticle interactions: Opportunities and challenges. Chem Rev 111(9):5610-5637.
26. Chow LW, Xu B, Gupta S, Freyman A, Zhao Y, Abbas R, Van MV, Bondarenko I. 2013. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Brit J Cancer 108(10):1985-1993.
27. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. 1999. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neuoverexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 5(2):343-353.
28. Vercauteren D, Rejman J, Martens TF, Demeester J, De Smedt SC, Braeckmans K. 2012. On the cellular processing of non-viral nanomedicines for nucleic acid delivery: Mechanisms and methods. J Control Release 161(2):566-581.
29. Jordan MA, Wilson L. 2004. Microtubules as a target for anticancer drugs. Nat Rev Cancer 4(4):253-265.
30. Yvon A, Wadsworth P, Jordan MA. 1999. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 10(4):947-959.
31. Gao H, Wang Y, Chen C, Chen J, Wei Y, Cao S, Jiang X. 2014. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int J Pharm 461(1-2):478-488.